

collection. Comments are requested concerning: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission’s burden estimates; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology. Pursuant to the Small Business Paperwork Relief Act of 2002, Public Law 107–198, see 44 U.S.C. 3506(c)(4), the FCC seeks specific comment on how it might “further reduce the information collection burden for small business concerns with fewer than 25 employees.”

*OMB Control Number:* 3060–0953.

*Title:* Section 95.2309, Frequency Coordination/Coordinator, Wireless Medical Telemetry Service.

*Form No.:* N/A.

*Type of Review:* Extension of a currently approved collection.

*Respondents:* Business or other for-profit and Not-for-profit institutions.

*Number of Respondents and*

*Responses:* 3,000 respondents; 3,000 responses.

*Estimated Time per Response:* 2–5 hours.

*Frequency of Response:* On occasion and one-time reporting requirements, third party disclosure requirement and recordkeeping requirement.

*Obligation to Respond:* Required to obtain or retain benefits. Statutory authority is contained in 47 U.S.C. 4(i), 302, 303(b), (c), (e), (f), (r), and 307.

*Total Annual Burden:* 15,000 hours.

*Total Annual Cost:* \$750,000.

*Privacy Act Impact Assessment:* No Impact(s).

*Nature and Extent of Confidentiality:* No information is requested that would require assurance of confidentiality.

*Needs and Uses:* The Commission will submit this information collection to OMB as an extension after this 60-day comment period to obtain the full three-year clearance from them. On March 20, 2019, the Federal Communications Commission released a Report and Order and Order on Reconsideration, Amendment of Part 15 of the Commission’s Rules for Unlicensed White Space Devices, Amendment of Part 15 of the Commission’s Rules for Unlicensed Operations in the Television Bands, Repurposed 600 MHz Band, 600 MHz Guard Bands and Duplex Gap, and Channel 37; Expanding the Economic and Innovation Opportunities of Spectrum Through Incentive Auctions, ET Docket Nos. 16–56, 14–165, GN Docket No 12–268 and RM–11745, FCC 19–24. The Federal Communications Commission restored previously deleted rule text to a new Section 95.2309 (h), which states that parties operating WMTS networks on Channel 37 (608–614 MHz) must notify one of the white space database administrators of their operating location to obtain interference protection from white space devices. The reinstatement did not impose any new requirements that would be subject to this collection of information.

Federal Communications Commission.

**Marlene Dortch,**

*Secretary, Office of the Secretary.*

[FR Doc. 2022–23965 Filed 11–2–22; 8:45 am]

**BILLING CODE 6712–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

[CFDA Number: 93.676]

**Announcement of the Intent To Award Single-Source Awards for Long Term Foster Care**

**AGENCY:** Office of Refugee Resettlement (ORR), Administration for Children and

Families (ACF), Department of Health and Human Services (HHS).

**ACTION:** Notice of Issuance of Single-Source Awards.

**SUMMARY:** ACF, ORR announces the intent to award five single-source awards in the amount of \$9,118,248, in multiple states across the country, for Long Term Foster Care (LTFC) services for Unaccompanied Children. ORR proposes to have the recipient conduct the following activities: provide additional capacity for long term placement services. The action is needed because ORR has a pending list with over 300 minors on it who need LTFC placement due to the unanticipated influx of unaccompanied children at the southwestern border in 2021 and the unforeseen arrival of Unaccompanied Afghan Minors (UAM) over the past year.

**DATES:** The proposed period of performance is October 1, 2022, through April 30, 2023.

**FOR FURTHER INFORMATION CONTACT:** Laura Kiesler, Director, Division of Unaccompanied Alien Children Operations, 330 C Street SW, Washington, DC 20447. Phone: 202–893–5037. Email: [laura.kiesler@acf.hhs.gov](mailto:laura.kiesler@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** ORR is continuously monitoring its capacity to shelter the unaccompanied children referred to LTFC services, as well as the information received from interagency partners to inform any future decisions or actions.

ORR has specific requirements for the provision of services. Award recipients must have the infrastructure, licensing, experience, and appropriate level of trained staff to meet those requirements.

ORR announces the intent to award the following single-source awards:

Recipient name	City & state	Proposed period of support budget (10/1/22–4/30/23)
Lutheran Immigration and Refugee Services .....	Moreno Valley, CA, Newport News, VA, & York, PA .....	\$1,653,049
Bethany Christian Services .....	Fresno and Modesto, CA & Grand Rapids, MI .....	3,958,841
Building Bridges Foster Family Agency .....	Southern CA .....	974,839
New Life Foster Family Agency .....	Colton, CA .....	1,465,532
Board of Child Care .....	Nicholasville and Owensboro, KY & Redford Charter TWP, MI.	1,065,987
<b>Total of Awards .....</b>		<b>9,118,248</b>

**Statutory Authority:** This program is authorized by:

(A) Section 462 of the Homeland Security Act of 2002, which in March 2003, transferred responsibility for the care and custody of unaccompanied alien children from the Commissioner of the former Immigration and Naturalization Service to the Director of ORR within HHS.

(B) The Flores Settlement Agreement, Case No. CV85–4544RJK (C. D. Cal. 1996), as well as the William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008 (Pub. L. 110–457), which authorizes post release services under certain conditions to eligible children. All programs must comply with the Flores Settlement Agreement, Case No. CV85–4544–RJK (C.D. Cal. 1996); pertinent regulations; and ORR policies and procedures.

(C) The Afghanistan Supplemental Appropriations Act, 2022, and Additional Afghanistan Supplemental Appropriation Act, 2022, designated funding for citizens and nationals of Afghanistan including UAM (Pub. L. 117–43 and Pub. L. 117–70). This funding is available to the Unaccompanied Children Program and is utilized by ORR to support the care and custody of UAM.

**Elizabeth A. Leo,**

Senior Grants Policy Specialist, Office of Grants Policy, Office of Administration.

[FR Doc. 2022–23960 Filed 11–2–22; 8:45 am]

**BILLING CODE 4184–45–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2022–N–1961]

#### Advancing Premarket Safety Analytics Workshop; Request for Comments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA, the Agency, or we) is requesting comments on the topics discussed at a public workshop entitled “Advancing Premarket Safety Analytics Workshop” held on September 14, 2022. The purpose of the public workshop was to present FDA’s work and perspective on premarket review of safety data.

**DATES:** Either electronic or written comments on this public workshop must be submitted by December 5, 2022. See the **SUPPLEMENTARY INFORMATION** section for information.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of December 5, 2022. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

#### Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

#### Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

**Instructions:** All submissions received must include the Docket No. FDA–2022–N–1961 for “Advancing Premarket Safety Analytics Workshop.” Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at

<https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

**Docket:** For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

**FOR FURTHER INFORMATION CONTACT:** Christopher Smith, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6230, Silver Spring, MD 20993, 301–796–4851, [christopher.smith2@fda.hhs.gov](mailto:christopher.smith2@fda.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

Because of a lack of standardization of safety data analysis and visualization, inconsistencies have been noted in how adverse events are defined, categorized, analyzed, and presented in marketing applications. The FDA Center for Drug Evaluation and Research’s (CDER’s)